Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor of phosphate transporter proteins NaPi-IIb, PiT-1, and PiT-2, has been granted breakthrough therapy designation (BTD) by the Center for Drug Evaluation. The drug is intended for the treatment of chronic kidney disease hyperphosphatemia.
As the world’s first and currently only drug of its kind to enter clinical trials, AP306 (EOS789) was originally discovered by Japanese pharmaceutical company Chugai Pharmaceutical Co. Ltd. In 2021, Chugai granted Alebund global development and commercialization rights for the drug. Alebund has successfully completed a Phase II clinical study for AP306 (EOS789).- Flcube.com
